[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100575849":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":23,"locations":29,"responsibleParty":46,"collaborators":10,"id":48,"slug":49,"hasResults":50,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":50,"sex":56,"minAge":57,"maxAge":10,"enrollmentInfo":58,"targetDuration":61,"studyType":62,"phases":10,"briefSummary":63,"conditions":64,"keywords":66,"overallStatus":32,"whyStopped":10,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":78},{"fullName":5,"class":6},"IRCCS Azienda Ospedaliero-Universitaria di Bologna","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"HCC patients",null,"Patients with advanced HCC undergoing immunotherapy",[13],"Drug: Immunochemotherapy combined with antiangiogenic",[15],{"type":16,"name":17,"description":17,"armGroupLabels":18,"otherNames":10},"DRUG","Immunochemotherapy combined with antiangiogenic",[9],[20],{"name":21,"affiliation":5,"role":22},"Laura Gramantieri","PRINCIPAL_INVESTIGATOR",[24],{"name":25,"role":26,"phone":27,"phoneExt":10,"email":28},"Laura Gramantieri, MD","CONTACT","0512142579","laura.gramantieri@aosp.bo.it",[30],{"facility":31,"status":32,"city":33,"state":21,"zip":34,"country":35,"countryCode":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"IRCCS-Azienda Ospedaliero-Universitaria di Bologna","RECRUITING","Bologna","40138","Italy","IT",{"type":38,"coordinates":39},"Point",[40,41],11.33875,44.49381,{"lat":41,"lon":40},[44],{"name":25,"role":26,"phone":45,"phoneExt":10,"email":28},"+390512142214",{"type":47,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100575849","immunophenotype-of-pbmc-to-early-predict-response-to-immunotherapy-in-hepatocellular-carcinoma-100575849",false,"NCT06777628","Immunophenotype of PBMC to Early Predict Response to Immunotherapy in Hepatocellular Carcinoma","Immunophenotype of Peripheral Blood Mononuclear Cells to Early Predict Response to Immunotherapy in Hepatocellular Carcinoma","Immunecheck","Inclusion Criteria:\n\n* age ≥ 18 years\n* diagnosis of HCC\n* execution of laboratory tests and subsequent treatments and follow-up at our center.\n* obtained written informed consent to the study participation\n\nExclusion Criteria:\n\n* immune-related concomitant diseases\n* HIV infection","ALL","18 Years",{"count":59,"type":60},100,"ESTIMATED","3 Years","OBSERVATIONAL","The study is aimed to test the performance of a simple, easy, reproducible cytofluorimetric assay to complement imaging studies for:\n\n* predicting response to immune-therapeutic regimens in HCC in the early phase of treatment,\n* to rule out pseudo-progression,\n* to early predict the escape from effectiveness of treatment.",[65],"Liver Cancer, Adult",[67,9,68],"immunophenotype","immunotherapy","2025-01-14",{"date":71,"type":72},"2025-01-16","ACTUAL",{"date":74,"type":72},"2024-09-15",{"date":76,"type":60},"2028-10-15",{"name":5,"class":6},1]